Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the closing of an $80 million Series B financing. The financing was led by Foresite Capital.
The WilmerHale team representing Fulcrum in this transaction included Lia Der Marderosian, Stephanie Singer and Andrea Sorrentino.
Fulcrum’s press release is available at www.fulcrumtx.com.
We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.
